
In the MagnetisMM-1 study, elranatamab induces response with tolerable safety in patients with relapsed or refractory multiple myeloma.

In the MagnetisMM-1 study, elranatamab induces response with tolerable safety in patients with relapsed or refractory multiple myeloma.

Following its success in acute myeloid leukemia and other cancers, devimistat is being explored as a treatment option for clear cell sarcoma in a phase 1/2 trial.

Pembrolizumab led to improvement in overall survival compared to placebo in patients with advanced hepatocellular carcinoma previously treated with sorafenib.

According to early clinical trial results, taletrectinib can induce responses in patients with ROS1-positive non–small cell lung cancer.

The FDA has accepted a supplemental biologic application for nivolumab plus ipilimumab and chemotherapy as a potential treatment option for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

In an interview with Targeted Oncology™, Ingrid Glimelius, MD, PhD, discusses the importance of long-term surveillance in lymphoma survivors.

In an interview with Targeted Oncology during the SOHO Annual Meeting, Elisabetta Abruzzese, MD, provided key recommendations for managing pregnancy and chronic myeloid leukemia.

Results from a mantle cell lymphoma study provide critical real-world evidence for improved outcomes with evolving patterns of care in patients with mantle cell lymphoma, according to the study authors.

ACCC announces the release of five abstracts to be presented during the ongoing ASCO Quality Care Symposium.

The phase 3 PROpel clinical trial has achieved its primary end point of improvement in radiographic progression-free survival in men with metastatic castration resistant prostate cancer using the novel combination of olaparib and abiraterone.

The FDA authorized the marketing of Paige Prostate, the first ratification-intelligence-based software designed to identify areas with high likelihood of cancer on images from a prostate biopsy.

Add-on parsaclisib showed improvement in spleen volume and symptoms in patients with myelofibrosis who were having a suboptimal response to a stable dose of ruxolitinib.

Robert Coleman, MD, FACOG, FACS, discussed how immunotherapy in lung cancer has been widely accepted and adopted in the community oncology setting.

In an interview with Targeted Oncology, Michael Wang, MD, discussed the evolution of treatment in the MCL space specifically with the emergence of chimeric antigen receptor T cells.

Compared with historic controls, the use of adjuvant VAL-083 after chemoradiotherapy and temozolomide may improve outcomes for select patients with glioblastoma multiforme.

Alrizomadlin, a MDM2-p53 inhibitor has been granted a fast track designation by the FDA for the treatment of relapsed/refractory unresectable or metastatic melanoma who are relapsed or refractory to prior immune-oncologic agents.

GenesisCare and Lee Health announce their efforts to transform pancreatic patient survival rates in Florida.

Lori Wirth, MD, discusses the relevance of patient-reported outcomes from the phase 1/2 LIBRETTO-001 study in of selpercatinib in patients with RET-altered medullary thyroid cancer or advanced thyroid cancer.

Findings from the phase 2 REGOBONE study revealed that regorafenib did not confer progression-free survival benefit in patients with advanced or metastatic chordoma.

Srdan Verstovsek, MD, PhD, discussed the future of myelofibrosis treatment, unmet clinical needs in this patient population, and new therapy options in an interview with Targeted Oncology™.

In patients with KRAS-mutant non–small cell lung cancer, treatment with rigosertib in combination with nivolumab showed promising signals of efficacy and safety.

Preliminary research suggests that lopofosine I-131 in combination with external beam radiation is safe and tolerable in patients with relapsed or refractory head and neck cancer.

The FDA has approved ruxolitinib for the treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.

The FDA has granted fast track designation to the HER2-targeted chimeric antigen receptor-macrophage, CT-0508, for the treatment of patients with solid tumors.

A biologics license application has been submitted to the FDA for betibeglogene autoemcel gene therapy for the treatment of adult, adolescent, and pediatric patients with B-thalassemia who require regular blood cell transfusions.

American Oncology Network, LLC and Sarah Cannon Research Institute announced today the addition of American Oncology Network partner practice Genesis Cancer and Blood Institute.

Tisotumab vedotin has become the first and only approved antibody-drug conjugate for the treatment of recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

In an interview with Targeted Oncology™ during the SOHO Annual Meeting, Carole Miller, MD, discussed results from the REVEAL study and how the findings can be used to aid future research.

In an interview with Dana Chase, MD during the ESMO Congress 2021, Chase discussed unmet needs for frontline advanced ovarian cancer treatment and the retrospective analysis of cumulative risk factors and their potential impact on outcome in these patients.

The FDA has approved cabozantinib for the treatment of patients 12 years of age and older with locally advanced or metastatic differentiated thyroid cancer that has progressed following prior vascular endothelial growth factor receptor-targeted therapy and who are radioactive iodine-refractory or ineligible.